| Old Articles: <Older 21531-21540 Newer> |
|---|
 |
The Motley Fool
March 15, 2007
Rick Aristotle Munarriz |
MIVA Searches for Answers The paid search pioneer has a tough time finding profitability in its latest quarter. Investors, take note.   |
The Motley Fool
March 15, 2007
Rich Duprey |
Candela Eases the Pain The aesthetic laser maker acquires an innovative technology that minimizes pain. Investors, it's essentially an investment in the future, but one that still entails some risk. |
The Motley Fool
March 15, 2007
Rick Aristotle Munarriz |
Google vs. Apple: Google In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." How twisted is it to have Google and Apple meet in the first round? |
The Motley Fool
March 15, 2007 |
Boston Beer on Tap: Fool by Numbers The brewer released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 15, 2007 |
eCollege.com Drops a Class: Fool by Numbers The online educator released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 15, 2007 |
Hibbett Sports Keeps Running: Fool by Numbers The sporting goods retailer released fourth-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
March 15, 2007
Rick Aristotle Munarriz |
Jumping Jupiter Goes Splat The digital snapshot provider finally announced its earnings and the real sore spot comes in its outlook for the current quarter. Investors, take note. |
The Motley Fool
March 15, 2007
Nathan Parmelee |
Microsoft vs. Johnson & Johnson: Microsoft In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Both businesses have defensible moats, pay increasing dividends, and trade at a reasonable price. |
The Motley Fool
March 15, 2007
Rich Duprey |
Biolase's Brighter Sales Figures With a firm financial footing in place, even after its shares have risen 50% in the past three months, Biolase could be an addition to your portfolio worth smiling about. |
The Motley Fool
March 15, 2007
Anders Bylund |
Dueling Fools: Elan Bull Rebuttal Do your due diligence and place your free bets on that Alzheimer's treatment or nano drug delivery system today. Tysabri simply isn't the massive risk some have made it out to be. |
| <Older 21531-21540 Newer> Return to current articles. |
